Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia

References

• EndoAKurodaMTanzawaKCompetitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236 A and ML-236B fungal metabolites, having hypocholesterolemic activityFEBS Lett197672232332616386050
   PubMed Web of Science ®Google Scholar
• ShepherdJCobbeSMFordIPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study GroupN Engl J Med199533320130113077566020
   PubMed Web of Science ®Google Scholar
• DownsJRClearfieldMWeisSPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention StudyJAMA199827920161516229613910
   PubMed Web of Science ®Google Scholar
• SacksFMPfefferMAMoyeLAThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigatorsN Engl J Med199633514100110098801446
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study GroupRandomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Simvastatin Survival Study (4S)Lancet19943448934138313897968073
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFAJUPITER Study GroupRosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN Engl J Med2008359212195220718997196
   PubMed Web of Science ®Google Scholar
• McClureDLValuckRJGlanzMMurphyJRHokansonJEStatin and statin-fibrate use was significantly associated with increased myositis risk in a managed care populationJ Clin Epidemiol200760881281817606177
   PubMed Web of Science ®Google Scholar
• SakaedaTFujinoHKomotoCEffects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transportPharm Res200623350651216388406
   PubMed Web of Science ®Google Scholar
• NeuvonenPJNiemiMBackmanJTDrug interactions with lipid-lowering drugs: Mechanisms and clinical relevanceClin Pharmacol Ther200680656558117178259
   PubMed Web of Science ®Google Scholar
• KuriharaYDouzonoTKawakitaKNagasakaYA large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO® Tablet) – LIVALO Effectiveness and Safety (LIVES) StudyJpn Pharmacol Ther2008368709731
   Google Scholar
• SaitoYCritical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goalsVasc Health Risk Manag2009592193619997573
   PubMedGoogle Scholar
• JadhavSBJainGKStatins and osteoporosis: New role for old drugsJ Pharm Pharmacol200658131816393459
   PubMed Web of Science ®Google Scholar
• KajinamiKMabuchiHSaitoYNK-104: A novel synthetic HMG-CoA reductase inhibitorExpert Opin Investig Drugs200091126532661
   PubMed Web of Science ®Google Scholar
• McKenneyJMNew cholesterol guidelines, new treatment challengesPharmacotherapy200222785386312126219
   PubMed Web of Science ®Google Scholar
• NozueTYamamotoSTohyamaSKanagawa PTCA Conference Study GroupTreatment with statin on atheroma regression evaluated by intravascular ultrasound with Virtual Histology (TRUTH Study): Rationale and designCirc J200973235235519110505
   PubMed Web of Science ®Google Scholar
• MiyauchiKKimuraTMorimotoTJapan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): Rationale and designCirc J200670121624162817127811
   PubMed Web of Science ®Google Scholar
• RashidMTawaraSFukumotoYSetoMYanoKShimokawaHImportance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitorsCirc J200973236137019060417
   PubMed Web of Science ®Google Scholar
• YokoyamaTMiyauchiKKurataTSatohHDaidaHInhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stentingAtherosclerosis2004174225325915136055
   PubMed Web of Science ®Google Scholar
• KokudaiMInuiNTakeuchiKSakaedaTKagawaYWatanabeHEffects of statins on the pharmacokinetics of midazolam in healthy volunteersJ Clin Pharmacol200949556857319398603
   PubMed Web of Science ®Google Scholar
• DiBSuMXYuFSolid-phase extraction and liquid chromatography/tandem mass spectrometry assay for the determination of pitavastatin in human plasma and urine for application to Phase I clinical pharmacokinetic studiesJ Chromatogr B Analyt Technol Biomed Life Sci20088681–295101
   PubMed Web of Science ®Google Scholar
• DengJWSongISShinHJThe effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: The contribution of transporting activity changes by SLCO1B1*15Pharmacogenet Genomics200818542443318408565
   PubMed Web of Science ®Google Scholar
• AndoHTsuruokaSYanagiharaHEffects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatinBr J Clin Pharmacol200560549449716236039
   PubMed Web of Science ®Google Scholar
• ChungJYChoJYYuKSEffect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteersClin Pharmacol Ther200578434235016198653
   PubMed Web of Science ®Google Scholar
• SakamotoTKojimaSOgawaHMUSASHI-AMI InvestigatorsUsefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: Subanalysis of MUSASHI-AMICirc J2007719134835317721009
   PubMed Web of Science ®Google Scholar
• OnoKKawasakiMTanakaRIntegrated backscatter and intima-media thickness of the thoracic aorta evaluated by transesophageal echocardiography in hypercholesterolemic patients: Effect of pitavastatin therapyUltrasound Med Biol200935219320018977068
   PubMed Web of Science ®Google Scholar
• MizuguchiYOishiYMiyoshiHIuchiANagaseNOkiTImpact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemiaCirc J200872453854418362422
   PubMed Web of Science ®Google Scholar
• SakabeKFukudaNFukudaYComparisons of short-and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial functionInt J Cardiol2008125113613817400311
   PubMed Web of Science ®Google Scholar
• NakamuraTSugayaTKawagoeYSuzukiTInoueTNodeKEffect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney diseaseAm J Nephrol2006261828616534182
   PubMed Web of Science ®Google Scholar
• NakamuraTSugayaTKawagoeYUedaYOsadaSKoideHEffect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathyDiabetes Care200528112728273216249547
   PubMed Web of Science ®Google Scholar
• YoshidaOKondoTKureishi-BandoYSugiuraPitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokersCirc J201074119520219926918
   PubMed Web of Science ®Google Scholar
• MiyashitaYEndoKSaikiAEffects of pitavastatin, a 3-hydroxy-3-methylglutarylcoenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patientsJ Atheroscler Thromb200916553954519907100
   PubMed Web of Science ®Google Scholar
• NakamuraTSatoEFujiwaraNCo-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent mannerPharmacol Res2010611586119666118
   PubMed Web of Science ®Google Scholar
• NomuraSInamiNShouzuAThe effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patientsPlatelets2009201162219172517
   PubMed Web of Science ®Google Scholar
• NakamuraTObataJEKittaYRapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndromeJ Cardiovasc Pharmacol200851436537118427279
   PubMed Web of Science ®Google Scholar
• SaitoYYamadaNTeramotoTClinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparisonArzneimittelforschung200252425125512040967
   PubMed Web of Science ®Google Scholar
• YoshitomiYIshiiTKanekiMEfficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: Results of a 12-week, open label studyJ Atheroscler Thromb
   Web of Science ®Google Scholar
• NozueTMichishitaIItoYHiranoTEffects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemiaJ Atheroscler Thromb200815314615318603821
   PubMed Web of Science ®Google Scholar
• KawashiriMANoharaATadaHComparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: Results from a crossover studyClin Pharmacol Ther200883573173917957184
   PubMed Web of Science ®Google Scholar
• SasakiJIkedaYKuribayashiTA 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intoleranceClin Ther20083061089110118640465
   PubMed Web of Science ®Google Scholar
• HiroTKimuraTMorimotoTJAPAN-ACS InvestigatorsEffect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: A multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study)J Am Coll Cardiol200954429330219608026
   PubMed Web of Science ®Google Scholar
• ToiTTaguchiIYonedaSEarly effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatinCirc J20097381466147219531899
   PubMed Web of Science ®Google Scholar
• SansanayudhNWongwiwatthananukitSPutwaiPDhumma-UpakornRComparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemiaAnn Pharmacother201044341542320179259
   PubMed Web of Science ®Google Scholar
• YokoteKBujoHHanaokaHMulticenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study)Atherosclerosis2008201234535218472103
   PubMed Web of Science ®Google Scholar
• LeeSHChungNKwanJComparison of the efficacy and tolerability of pitavastatin and atorvastatin: An 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemiaClin Ther200729112365237318158077
   PubMed Web of Science ®Google Scholar
• SaitoYYamadaNTeramotoTA randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemiaAtherosclerosis2002162237337911996957
   PubMed Web of Science ®Google Scholar
• ParkSKangHJRimSJA randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemiaClin Ther20052771074108216154486
   PubMed Web of Science ®Google Scholar
• OseLBudinskiDHounslowNArnesonVComparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemiaCurr Med Res Opin200925112755276419785568
   PubMed Web of Science ®Google Scholar
• BudinskiDArnesonVHounslowNGratsianskyNPitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemiaJ Clin Lipidol200943291302
   Google Scholar
• HounslowNJEfficacy and safety of pitavastatin compared to pravastatin in elderly patients with primary hypercholesterolemia or combined dyslipidemiaJ Clin Lipidol200715439
   Google Scholar
• TeramotoTSaitoYYamadaNClinical safety and efficacy of NK-104 (pitavastatin), a new synthetic HMG-CoA reductase inhibitor, in the long-term treatment of hyperlipidemia – results of a multicenter long-term studyJ Clin Therap Med2001176885913 Japanese
   Google Scholar
• NojiYHigashikataTInazuAHokuriku NK-104 Study GroupLong-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemiaAtherosclerosis2002163115716412048134
   PubMed Web of Science ®Google Scholar
• TeramotoTShimanoHYokoteKUrashimaMEffects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemiaJ Atheroscler Thromb200916565466119907105
   PubMed Web of Science ®Google Scholar
• OseLBudinskiDHounslowNArnesonVLong-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemiaAtherosclerosis2010210120220820080236
   PubMed Web of Science ®Google Scholar